Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Company to update past 8-months work- a lot in the pipeline

<< Previous

Bullboard Posts

Next >>

Comment by KILOFINALon Mar 01, 2021 7:24pm

156 Views

Post# 32691553

RE:Company to update past 8-months work- a lot in the pipeline

Agree. Don't think they would have chosen this specific time to launch the new company and business strategy unless they were well on their way to achieving the results they expect

Rezjen wrote:
Read between the lines in Today's NR- as this story unfolds to the market, the world will have a solution for Covid-19

More interesting when Ceo says "We intend to become a leader in the race to find a treatment for COVID-19, and we are well positioned to achieve this goal,”

it sounds they are way ahead in the game and knows exactly what they are doing!

long enjoy the ride!!!